Philadelphia, PANCT06586255Now EnrollingIRB Ready

Urothelial Carcinoma Bladder Clinical Trial in Philadelphia, PA

Access cutting-edge urothelial carcinoma bladder treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by Abramson Cancer Center at Penn Medicine

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access urothelial carcinoma bladder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related urothelial carcinoma bladder treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this urothelial carcinoma bladder clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Urothelial Carcinoma Bladder Study in Philadelphia

The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.

Sponsor: Abramson Cancer Center at Penn Medicine

Who Can Participate

Inclusion Criteria

Pure or mixed variant urothelial carcinoma o Allowable mixed variant subtypes include:
squamous differentiation
glandular differentiation
nested pattern
microcystic
micropapillary
lymphoepthelioma-like
plasmacytoid and lymphoma-like
sarcomatoid/carcinosarcoma
trophoblastic differentiation
undifferentiated
Radical cystectomy and pelvic lymph node dissection within the prior 48 weeks
Pathologic T3 or higher stage disease, any N, M0 (AJCC, 7th Ed., Appendix C)
Receiving adjuvant checkpoint inhibitor therapy
No clinical evidence of residual or recurrent disease based on the following minimum diagnostic work-up within 3 months of a patient's consent to participate.
History and physical examination
Chest imaging by x-ray (PA and lateral views), CT scan (with or without IV contrast) or as part of a FDG PET-CT;
Axial abdominal and pelvic imaging by MRI (preferably with gadolinium), CT scan (with or without IV contrast) or as part of a FDG PET-CT;
Patients with microscopically involved (positive) surgical margins, but no grossly evident residual disease by imaging or physical exam are eligible.
The patient is a candidate for definitive external beam radiotherapy;
No prior radiotherapy to the region of study;
No inflammatory bowel disease, active collagen vascular or connective tissue disorders, and no other medical or social contraindications to radiotherapy, as determined by a participating radiation oncologist;
Age greater than or equal to 18 years
ECOG performance status: 0-2
Concurrent non-investigational medications will be permitted
In addition to diagnostic staging scan, patient will be considered eligible only if he/she has a CT simulation scan that does not show any evidence of recurrent disease
Informed consent: Patients must have the ability to understand and be willing to sign the study-specific informed consent indicating their understanding of the investigational nature and the risks of this study before any of the protocol related studies are performed (this does not include routine laboratory testing or imaging studies required to establish study eligibility)

Exclusion Criteria

Urinary diversion with an orthotopic neobladder
History of inflammatory bowel disease
Prior partial or complete small bowel obstruction either before or after radical cystectomy
Prior radiotherapy to the pelvis; o Prior radiation therapy for a different cancer or disease process is allowed, provided there will be no overlap of radiation therapy fields between the participant's prior and current course of radiation therapy, radiotherapy was completed more than four weeks from enrolling in this study.
Planned concurrent chemotherapy or other investigational drug to be given with radiation treatments o Prior chemotherapy or investigational drug for bladder cancer or a different cancer is allowed, provided that:
The therapy was completed more than two weeks prior to the start of adjuvant pelvic radiation
The participant has recovered to Grade ≤1 toxicity from agents previously administered, excluding toxicities that would not be expected to impact eligibility for radiation therapy including but not limited to neuropathy, alopecia and hearing loss.
Subtotal surgical resection with clinically evident residual disease by physical exam or axial imaging.
Prior or concurrent second invasive malignancy that, in the judgment of the investigator, may affect interpretation of the results.
Known severe, active co-morbidity, defined as follows: o Any clinically significant unrelated systemic illness, medical condition, or other factor, which at the discretion of the Principal Investigators, would interfere in the safe and timely completion of study procedures, compromise the patient's ability to tolerate the protocol therapy, or is likely to interfere with the study procedures or results.
Patients who experienced Grade 3+ GI toxicity due to surgery or nivolumab prior to enrollment in the trial

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT06586255) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Urothelial Carcinoma Bladder Treatment Options in Philadelphia, PA

If you're searching for urothelial carcinoma bladder treatment options in Philadelphia, PA, this clinical trial (NCT06586255) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced urothelial carcinoma bladder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all urothelial carcinoma bladder clinical trials near you to find additional studies recruiting in your area.

More Bladder Cancer Trials in Philadelphia, PA

See all bladder cancer clinical trials recruiting in Philadelphia — not just this study.

Browse Bladder Cancer Trials in Philadelphia →

Browse More Trials by Condition

Bladder Cancer TrialsAlzheimers Disease TrialsADHD TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA